Lincoln PharmaceuticalsNSE:LINCOLN -3.03%82 Days Payable is 86.94 as of Mar. 2026, which is 12% below its 10-year median of 98.25. GuruFocus rates NSE:LINCOLN with a GF Score™ of 82/100 and a GF Value™ of ₹707.41 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Lincoln Pharmaceuticals ranks better than 55.42% on this metric.
The historical rank and industry rank for Lincoln Pharmaceuticals's Days Payable or its related term are showing as below:
NSE:LINCOLN'
s Days Payable Range Over the Past 10 Years
Min: 60.16 Med: 98.25 Max: 106.89
Current: 100.99
During the past 13 years, Lincoln Pharmaceuticals's highest Days Payable was 106.89. The lowest was 60.16. And the median was 98.25.
NSE:LINCOLN's Days Payable is ranked better than 55.42% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs NSE:LINCOLN: 100.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lincoln Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Lincoln Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lincoln Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lincoln Pharmaceuticals (NSE:LINCOLN) has a Days Payable of 86.94 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lincoln Pharmaceuticals and its competitors. This is 12% below median its historical median of 98.25. Over the past decade, Lincoln Pharmaceuticals' Days Payable has ranged from 60.16 to 106.89. According to the industry distribution chart, Lincoln Pharmaceuticals ranks #411 out of 922 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Lincoln Pharmaceuticals' Days Payable too high?
Lincoln Pharmaceuticals' current Days Payable of 86.94 is 12% below median its 10-year median of 98.25. Over the past 10 years, this metric has ranged from a low of 60.16 to a high of 106.89. The Drug Manufacturers industry median Days Payable is 90.61. Lincoln Pharmaceuticals' value of 86.94 is 4.1% below this industry median. Based on the distribution chart, Lincoln Pharmaceuticals ranks #411 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lincoln Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lincoln Pharmaceuticals ranks #411 out of 922 companies for Days Payable. This puts Lincoln Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 90.61. Lincoln Pharmaceuticals' value of 86.94 is 4.1% below this benchmark. Historically, Lincoln Pharmaceuticals' own Days Payable has ranged from 60.16 to 106.89 over the past decade. While the company's 10-year median is 98.25 vs. the industry median of 90.61, Lincoln Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lincoln Pharmaceuticals's current Days Payable of 86.94 is 4.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lincoln Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lincoln Pharmaceuticals's current Days Payable is 86.94, which is 12% below median its own 10-year median of 98.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹707.41, compared to a current price of ₹600.90 — trading 15.1% below its estimated fair value. The current Days Payable is 86.94, which is 12% below median its 10-year median of 98.25 and 4.1% below the Drug Manufacturers industry median of 90.61. Lincoln Pharmaceuticals' overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current Days Payable is 86.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹600.90 is trading 15.1% below its estimated GF Value™ of ₹707.41.
GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:LINCOLN:
Days Payable: 86.94 (12% below median its 10-year median of 98.25)
GF Value™: ₹707.41 vs. price of ₹600.90 (15.1% below fair value)
Industry Position: 4.1% below the Drug Manufacturers median (#411 of 922)
No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
82GF Score
Get the complete analysis for NSE:LINCOLN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LINCOLN has been successfully added to your 
